Five Years Later, Legacy Biologics Still Face ‘Next Heparin’ Risks
This article was originally published in The Gold Sheet
Several factors continue to slow efforts to modernize legacy biologics’ compendial monographs against fake ingredients like the ones someone put in heparin in 2008. Hyaluronate, the ‘poster child’ for monograph modernization; New NDAs for pancreatin create new modernization challenges; Heparin maker vertically integrates to prevent adulteration.
You may also be interested in...
Officials with FDA, the U.S. Pharmacopeia and the pharmaceutical industry are looking for a quicker way to remedy a situation underscored by the 2008 heparin crisis: the need to update hundreds, perhaps thousands of the compendial standards that the U.S. Pharmacopeia developed and FDA enforces.
New tests raise bar against adulterants, counterfeits as USP adds instrumental methods for heparin ID test and drops compromised sheep clotting assay, while revising the glycerin ID test to include a DEG limit and making overtures to FDA's incoming leadership to strengthen their partnership. Meanwhile, FDA's forensic lab gives some insight into its methods for catching drug counterfeiters, the agency's St. Louis lab explains how it found adulterants in ED supplements, and the Army shares its methods for spotting biowarfare pathogens.
A fresh executive order from US president Joe Biden calls for short-term and long-term study, broad consultation, and co-ordination with allies on the domestic supply chain.